Multiple innovative platforms are currently available for antibody discovery using genetically modified mice that express fully-human heavy and light chain variable regions. These animals can generate diverse repertoires of in vivo affinity-matured antibodies with intrinsic drug-like properties necessary for successful development, including high potency, specificity, solubility, and manufacturability. A key advantage is that in having full-human variable regions, the antibodies have a low risk of immunogenicity, thus mitigating efficacy-killing anti-drug responses when reformatted as therapeutics.
References Lowitz J, Lin G, Somera J, Santibanez-Vargas L, Vo C, Rodriguez E, Nguyen B, Trang M, Nichols J, Kenney J. Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms. Poster presented at PEGS; 2019 Apr. 8-12; Boston, MA.Maximizing the AlivaMab Mouse Advantage. Retrieved from https://alivamab.com/alivamab-mouse.